Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Nov. 30, 2015	Jan. 12, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-Q
Document Period End Date	Nov. 30, 2015
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,095,661

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Nov. 30, 2015	Aug. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 1,949	$ 3,213
Short term deposits	11,127	11,928
Marketable securities	1,984	2,088
Restricted cash	16	16
Prepaid expenses and other current assets	112	127
Total current assets	15,188	17,372
LONG TERM ASSETS:
Long term deposits and investment	8,051	8,022
Marketable securities	623	940
Amounts funded in respect of employee rights upon retirement	9	9
Property and equipment, net	12	11
Total long term assets	8,695	8,982
Total assets	23,883	26,354
CURRENT LIABILITIES:
Accounts payable and accrued expenses	768	953
Advance on account of license agreement (see note 1a1)	500	500
Related parties	36	36
Total current liabilities	1,304	1,489
LONG TERM LIABILITIES:
Employee rights upon retirement	12	11
Provision for uncertain tax position	26	26
Total long term liabilities	$ 38	$ 37
COMMITMENTS (note 2)
STOCKHOLDERS' EQUITY:
Common stock, $0.012 par value (30,000,000 authorized shares; 11,602,652 and 11,563,077 shares issued and outstanding as of November 30, 2015 and August 31, 2015, respectively)	$ 138	$ 138
Additional paid-in capital	59,693	59,184
Accumulated other comprehensive income	152	558
Accumulated loss	(37,442)	(35,052)
Total stockholders' equity	22,541	24,828
Total liabilities and stockholders' equity	$ 23,883	$ 26,354

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Nov. 30, 2015	Aug. 31, 2015
Balance Sheets [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	11,602,652	11,563,077
Common stock, shares outstanding	11,602,652	11,563,077

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
Income Statement [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, NET	$ 1,901	$ 1,302
GENERAL AND ADMINISTRATIVE EXPENSES	548	600
OPERATING LOSS	2,449	1,902
FINANCIAL INCOME	(76)	(27)
FINANCIAL EXPENSES	17	21
NET LOSS FOR THE PERIOD	2,390	1,896
UNREALIZED LOSS ON AVAILABLE FOR SALE SECURITIES	406	359
TOTAL OTHER COMPREHENSIVE LOSS	406	359
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 2,796	$ 2,255
LOSS PER SHARE OF COMMON STOCK:
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.21	$ 0.19
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	11,572,809	10,142,013

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - 3 months ended Nov. 30, 2015 - USD ($)
$ in Thousands

Total

Common Stock

Additional paid-in capital

Accumulated other comprehensive income

Accumulated loss

BEGINNING BALANCE at Aug. 31, 2015

$ 24,828

$ 138

$ 59,184

$ 558

$ (35,052)

BEGINNING BALANCE, Shares at Aug. 31, 2015

11,563

SHARES ISSUED FOR SERVICES

^[1]

SHARES ISSUED FOR SERVICES, Shares

EXERCISE OF WARRANTS

164

^[1]

164

EXERCISE OF WARRANTS, Share

STOCK BASED COMPENSATION

320

^[1]

$ 320

STOCK BASED COMPENSATION, Shares

NET LOSS

(2,390)

$ (2,390)

OTHER COMPREHENSIVE LOSS

(406)

$ (406)

ENDING BALANCE at Nov. 30, 2015

$ 22,541

$ 138

$ 59,693

$ 152

$ (37,442)

ENDING BALANCE, Shares at Nov. 30, 2015

11,603

[1]	Represents an amount of less than $1.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,390)	$ (1,896)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	1	1
Exchange differences and interest on investments	(34)	(9)
Stock based compensation	320	300
Common stock issued for services	25	26
Changes in operating assets and liabilities:
Prepaid expenses, other current assets and related parties	15	325
Accounts payable, accrued expenses and related parties	(185)	$ (146)
Liability for employee rights upon retirement	1
Total net cash used in operating activities	(2,247)	$ (1,399)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(2)	(2)
Purchase of short term deposits	(600)	(820)
Proceeds from sale of short term deposits	$ 1,420	2,300
Other		(2)
Total net cash derived from investing activities	$ 818	$ 1,476
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants	$ 164
Proceeds from issuance of common stock - net of issuance expenses		$ 4,833
Net cash derived from financing activities	$ 164	4,833
EFFECT OF EXCHANGE RATE CHANGES ON CASH	1	(16)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(1,264)	4,894
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,213	1,762
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 1,949	$ 6,656

Significant Accounting Policies

3 Months Ended

Nov. 30, 2015

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Incorporation and operations

Oramed Pharmaceuticals Inc. (the “Company”) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development. Unless the context indicates otherwise, the term “Group” refers to Oramed Pharmaceuticals Inc. and its Subsidiary.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On November 30, 2015, the Company and the Subsidiary entered into Technology License Agreement (the “License Agreement”) with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”). According to the License Agreement, the Company will grant HTIT an exclusive commercialization license in the territory of the Peoples Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801. Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Company’s technology and ORMD-0801 capsule, and will pay to the Company (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 is payable immediately, $8,000 will be paid by September 2016, subject to the Company entering into certain agreements with certain third parties, and $26,500 will be payable upon achievement of certain milestones and conditions. In the event that the Company will not meet certain conditions the Royalties rate may be reduced to a minimum of 8%. Following the expiration of the Company's patents covering the technology in the Territory (the “Patents”), the Royalties rate may be reduced, under certain circumstances, to 5%.

The Royalties term will commence upon the commercialization of the product and will end upon the later of the expiration of the Patents or fifteen years after the first commercialization of the product in the Territory.

The closing of the License Agreement was conditioned upon the approval of the Israeli Chief Scientist, which was received on December 21, 2015.

In July 2015, according to the letter of intent signed between the parties or their affiliates, HTIT's affiliate paid the Subsidiary a non-refundable amount of $500 as a no-shop fee. The no-shop fee is presented as an advance on account of the License Agreement among current liabilities.

On December 21, 2015, the Company, its Subsidiary and HTIT entered into an Amended and Restated Technology License Agreement (the “A&R License Agreement”), which replaced the License Agreement between the parties. The material terms of the A&R License Agreement are the same as of the License Agreement. The closing conditions of the A&R License Agreement were met during December 2015, and the initial payment of $3,000 was received in January 2016.

In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement (“SPA”) with HTIT. For details see note 5.

The Company is evaluating the future revenue recognition of the agreement with HTIT.

Development and liquidity risks

The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.

Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Based on its current cash resources and commitments, and cash received in private and public offerings in the three month period ended November 30, 2015 and in the year ended August 31, 2015, as well as the investment made by HTIT, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months beyond the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding. Outstanding stock options, warrants and restricted stock units have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options, warrants and restricted stock units excluded from the calculation of diluted net loss was 2,940,137 and 1,933,520 for the three month periods ended November 30, 2015 and 2014, respectively.

Newly issued and recently adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017 (early adoption is permitted for the interim and annual periods beginning on or after December 15, 2016). The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

In January 2016, the FASB issued guidance on recognition and measurement of financial assets and financial liabilities (Accounting Standards Update No. 2016-01) that will supersede most current guidance. Changes to the current United States generally accepted accounting principles (“U.S. GAAP”) model primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities.

The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities, is largely unchanged. The classification and measurement guidance will be effective in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years (early adoption of the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income is permitted). The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with U.S. GAAP and on the same basis as the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015 (the “2015 Form 10-K”). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2015 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year’s results.

Commitments

3 Months Ended

Nov. 30, 2015

Commitments [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd (“Entera”) to D.N.A Biomedical Solutions Ltd (“D.N.A”) (see also note 4), retaining a 3% interest as of March 2011, which is accounted for as a cost method investment (amounting to $1). In consideration for the shares sold to D.N.A, the Company received a promissory note issued by D.N.A in the principal amount of $450, with an annual interest rate of 0.45% that was fully paid in November 2011, and 8,404,667 ordinary shares of D.N.A.

As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera’s net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of November 30, 2015, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.

On September 11, 2011, the Subsidiary entered into an agreement with Hadasit, the Company's Medical and Chief Technology Officer (the “CTO”) and Dr. Daniel Schurr (the “Hadasit Agreement”) to retain consulting and clinical trial services. According to the Hadasit Agreement, Hadasit will be entitled to consideration of $200 to be paid by the Company in accordance with the actual progress of the studies, $111 of which were recognized through November 30, 2015. See also note 1a(1).

On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel. The new lease agreement is for a period of 36 months commencing November 4, 2013.

The annual lease payment will be New Israeli Shekel 89 thousands from 2014 through 2016, and will be linked to the increase in the Israeli consumer price index (“CPI”) (as of November 30, 2015, the future annual lease payments under the new agreement will be $23, based on the exchange rate as of November 30, 2015).

As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On July 22, 2014, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party, to retain it as a Clinical Research Organization (“CRO”), for its Phase 2b clinical trial for an oral insulin capsule for type 2 diabetes patients, which began in the second quarter of calendar year 2015. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $3,290 during the term of the engagement and based on achievement of certain milestones, $2,388 of which were recognized through November 30, 2015.

On March 3, 2014, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $311, $40 of which was recognized through November 30, 2015, and bonus payments of up to $600 that will be paid upon achieving certain milestones, as described in the agreement, none of which was recognized through November 30, 2015.

On December 12, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of the same capsule ingredients in the amount of $550, $430 of which was recognized through November 30, 2015.

Grants from the Bio-Jerusalem Fund (“Bio-Jerusalem”)

The Subsidiary is committed to pay royalties to Bio-Jerusalem on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65.

During the three month period ended November 30, 2015, the Company received no grants from Bio-Jerusalem.

As of November 30, 2015, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.

Grants from the Office of Chief Scientist (“OCS”)

Under the terms of the Company’s funding from the OCS, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.

The total amount that was received through November 30, 2015 was $2,194.

On November 30, 2015, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability.

Fair Value

3 Months Ended

Nov. 30, 2015

Fair Value [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

	Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of November 30, 2015, the assets or liabilities measured at fair value are comprised of available for sale equity securities (level 1).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

As of November 30, 2015, the carrying amount of cash and cash equivalents, short term deposits, prepaid expenses and other current assets and accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments.

As of November 30, 2015, the carrying amount of long term deposits approximates their fair values due to the stated interest rates which approximate market rates.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

3 Months Ended

Nov. 30, 2015

Marketable Securities [Abstract]

MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES:

The Group's marketable securities include investments in equity securities of D.N.A and in held to maturity bonds.

Composition:

	November 30, 2015		August 31, 2015
Short term:
D.N.A (see b below)	$	747	$	1,153
Held to maturity bonds (see c below)		1,237		935
	$	1,984	$	2,088
Long term:
Held to maturity bonds (see c below)	$	623	$	940

D.N.A

The investment in D.N.A. is reported at fair value, with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

The D.N.A. ordinary shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

During the three month period ended November 30, 2015, the Group did not sell any of the D.N.A ordinary shares.

As of November 30, 2015, the Group owns approximately 8.7% of D.N.A’s outstanding ordinary shares.

The cost of the securities as of November 30, 2015 and August 31, 2015 is $590.

Held to maturity bonds

The amortized cost and estimated fair value of held-to-maturity securities at November 30, 2015, are as follows:

	November 30, 2015
	Amortized cost		Gross unrealized losses		Estimated fair value
Short term:
Commercial bonds	$	1,219	$	2	$	1,217
Accrued interest		18		-		18

Long term		623		2		621
	$	1,860	$	4	$	1,856

As of November 30, 2015, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $1,237, and the yield to maturity rates vary between 0.57% to 1.31%.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Stockholders' Equity	3 Months Ended
Stockholders' Equity	Nov. 30, 2015
Stockholders' Equity [Abstract]
STOCK HOLDERS' EQUITY	NOTE 5 - STOCK HOLDERS’ EQUITY On November 30, 2015, the Company entered into an SPA with HTIT, pursuant to which HTIT agreed to buy and the Company agreed to sell 1,155,367 restricted shares of common stock of the Company at a price of approximately $10.39 per share, for the aggregate amount of $12,000. The transaction closed and the consideration was received during December 2015.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Stock Based Compensation	3 Months Ended
Stock Based Compensation	Nov. 30, 2015
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION	NOTE 6 - STOCK BASED COMPENSATION On November 19, 2015, options to purchase an aggregate of 22,000 of the Company’s shares of common stock were granted to two consultants at an exercise price of $7.36 per share (equivalent to the traded market price on the date of grant). 10,000 of the options vest in one installment on December 1, 2015, and the remaining 12,000 options vest in twelve equal quarterly installments, commencing January 1, 2016. All the options will expire on November 19, 2025. The fair value of the options as of November 30, 2015 was $168, using the following assumptions: dividend yield of 0%; expected term of 9.98 years; expected volatility of 80.49%; and risk-free interest rate of 2.21%. The fair value of the unvested options is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

Subsequent Event	3 Months Ended
Subsequent Event	Nov. 30, 2015
Subsequent Event [Abstract]
SUBSEQUENT EVENT	NOTE 7 - SUBSEQUENT EVENT On January 4, 2016, the Company’s President, Chief Executive Officer and director (the “CEO”), in his personal capacity as a shareholder of the Company, and a leading investor of the Company, terminated a letter agreement dated November 29, 2012, between the parties, which entitled the leading investor to certain stock compensation from the CEO under certain conditions.

Significant Accounting Policies (Policies)

3 Months Ended

Nov. 30, 2015

Significant Accounting Policies [Abstract]

General

a.	General:

Incorporation and operations

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The closing of the License Agreement was conditioned upon the approval of the Israeli Chief Scientist, which was received on December 21, 2015.

In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement (“SPA”) with HTIT. For details see note 5.

The Company is evaluating the future revenue recognition of the agreement with HTIT.

Development and liquidity risks

Loss per common share

Loss per common share

Newly issued and recently adopted Accounting Pronouncements

Newly issued and recently adopted Accounting Pronouncements

Condensed Consolidated Financial Statements Preparation

Condensed Consolidated Financial Statements Preparation

Marketable Securities (Tables)

3 Months Ended

Nov. 30, 2015

Marketable Securities [Abstract]

Schedule of marketable securities include investments in equity securities

	November 30, 2015		August 31, 2015
Short term:
D.N.A (see b below)	$	747	$	1,153
Held to maturity bonds (see c below)		1,237		935
	$	1,984	$	2,088
Long term:
Held to maturity bonds (see c below)	$	623	$	940

Summary of held to maturity securities

	November 30, 2015		August 31, 2015
Short term:
D.N.A (see b below)	$	747	$	1,153
Held to maturity bonds (see c below)		1,237		935
	$	1,984	$	2,088
Long term:
Held to maturity bonds (see c below)	$	623	$	940

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

Significant Accounting Policies (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Dec. 31, 2015	Jul. 31, 2015	Nov. 30, 2015	Nov. 30, 2014
Significant Accounting Policies (Textual)
Securities excluded from the calculation of diluted net loss			2,940,137	1,933,520
Amended And Restated Technology License Agreement [Member] \| Subsequent Event [Member]
Significant Accounting Policies (Textual)
Initial payment of amended and restated technology license agreement	$ 3,000
Hefei Tianhui Incubation of Technologies Co. Ltd [Member]
Significant Accounting Policies (Textual)
Royalties percentage on net sales			10.00%
Aggregate principal payment			$ 37,500
Value held by subsidiary paid in front			3,000
Periodic payment of agreement			8,000
Value held by subsidiary payable upon achievement			$ 26,500
Royalty commitment description			In the event that the Company will not meet certain conditions the Royalties rate may be reduced to a minimum of 8%. Following the expiration of the Company's patents covering the technology in the Territory (the "Patents"), the Royalties rate may be reduced to 5%.
Nonrefundable subsidiary amount		$ 500

Commitments (Details) $ / shares in Units, ₪ in Thousands, $ in Thousands	1 Months Ended		3 Months Ended
	Nov. 19, 2015 $ / shares shares	Mar. 31, 2011 USD ($) shares	Nov. 30, 2015 USD ($)	Nov. 30, 2015 ILS (₪)	Nov. 30, 2014 USD ($)
Long-term Purchase Commitment [Line Items]
Options granted \| shares	22,000
Options granted, exercise price \| $ / shares	$ 7.36
Lease expenses \| ₪				₪ 89
Shares issued for services rendered			$ 25		$ 26
Total revenue			$ 2,194
Office Building [Member]
Long-term Purchase Commitment [Line Items]
Operating lease term			36 months	36 months
Annual lease payments 2015			$ 23
Bio Jerusalem [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage			4.00%
Royalty percentage maximum percentage of grants received			100.00%	100.00%
Grants receivable			$ 65
Chief Scientist Office [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage maximum percentage of grants received			100.00%	100.00%
Chief Scientist Office [Member] \| Minimum [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage maximum percentage of grants received			3.00%	3.00%
Chief Scientist Office [Member] \| Maximum [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage maximum percentage of grants received			3.50%	3.50%
Entera Bio [Member] \| D.N.A. [Member]
Long-term Purchase Commitment [Line Items]
Principal amount of promissory note received		$ 450
Interest rate		0.45%
Ownership percentage retained		3.00%
Ordinary shares received \| shares		8,404,667
Royalty percentage		3.00%
Hadasit [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services			$ 200
Consultant [Member]
Long-term Purchase Commitment [Line Items]
Consulting services			111
Clinical Research Organization Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services			3,290
Consulting services			2,388
First Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for bonus payments upon achieving certain milestones			600
Third Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services			311
Shares issued for services rendered			550
Fourth Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services			40
Shares issued for services rendered			$ 430

Marketable Securities (Details) - USD ($) $ in Thousands	Nov. 30, 2015	Aug. 31, 2015
Short term:
D.N.A (see b below)	$ 747	$ 1,153
Held to maturity bonds (see c below)	1,237	935
Marketable securities	1,984	2,088
Long term:
Held to maturity bonds (see c below)	$ 623	$ 940

Marketable Securities (Details1) $ in Thousands	Nov. 30, 2015 USD ($)
Net Investment Income [Line Items]
Amortized cost	$ 1,860
Gross unrealized losses	4
Estimated fair value	1,856
Long term [Member]
Net Investment Income [Line Items]
Amortized cost	623
Gross unrealized losses	2
Estimated fair value	621
Accrued interest [Member] \| Short term [Member]
Net Investment Income [Line Items]
Amortized cost	$ 18
Gross unrealized losses
Estimated fair value	$ 18
Commercial bonds [Member] \| Short term [Member]
Net Investment Income [Line Items]
Amortized cost	1,219
Gross unrealized losses	2
Estimated fair value	$ 1,217

Marketable Securities (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2015	Aug. 31, 2015
Marketable Securities (Textual)
Percentage of ownership interest	8.70%
Cost of securities	$ 590	$ 590
Held to maturity bonds	$ 1,237	$ 935
Maximum [Member]
Marketable Securities (Textual)
Yield to cost rates	1.31%
Minimum [Member]
Marketable Securities (Textual)
Yield to cost rates	0.57%

Stockholders' Equity (Details) - Securities Purchase Agreement With HTIT [Member] - Restricted common stock [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Nov. 30, 2015 USD ($) $ / shares shares
Related Party Transaction [Line Items]
Common stock agreed to sell, shares \| shares	1,155,367
Share price \| $ / shares	$ 10.39
Aggregate amount \| $	$ 12,000

Stock Based Compensation (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended
	Jan. 01, 2016 Installments shares	Dec. 01, 2015 Installments shares	Nov. 19, 2015 USD ($) $ / shares shares	Nov. 30, 2015 USD ($)
Stock-Based Compensation (Textual)
Expected dividend yield				0.00%
Expected volatility				80.49%
Options granted			22,000
Options granted, exercise price \| $ / shares			$ 7.36
Expiration date			Nov. 19, 2025
Fair value of options granted \| $			$ 168	$ 168
Risk-free interest rate				2.21%
Expected term				9 years 11 months 23 days
Subsequent Event [Member]
Stock-Based Compensation (Textual)
Options vested in period	12,000	10,000
Number of vesting installments \| Installments	12	1